Nuclear β-catenin expression as a prognostic factor in advanced colorectal carcinoma

World Journal of Gastroenterology

Volumn 14, Issue 24, 2008, Pages 3866-3871

  Elzagheid, Adam ^a,c   Buhmeida, Abdelbaset ^b   Korkeila, Eija ^b   Collan, Yryö ^a   Syrjänen, Kari ^b   Pyrhönen, Seppo ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c AL ARAB MEDICAL UNIVERSITY   (Libyan Arab Jamahiriya)

Author keywords

Colorectal carcinoma; Cytoplasmic staining; Disease free survival; Disease specific survival; Immunohistochemistry; Nuclear staining; Prognosis; catenin membrane staining

Indexed keywords

BETA CATENIN; FLUOROURACIL; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 54349109609     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3866     Document Type: Article

References (31)

1. Aberle H, Butz S, Stappert J, Weissig H, Kemler R, Hoschuetzky H. Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci 1994; 107 (Pt 12): 3655-3663
2. Barth AI, Nathke IS, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 1997; 9: 683-690
3. Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res 2001; 61: 6656-6659
4. Nilbert M, Rambech E. Beta-catenin activation through mutation is rare in rectal cancer. Cancer Genet Cytogenet 2001; 128: 43-45
5. Aust DE, Terdiman JP, Willenbucher RF, Chang CG, Molinaro-Clark A, Baretton GB, Loehrs U, Waldman FM. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 2002; 94: 1421-1427
6. Maruyama K, Ochiai A, Akimoto S, Nakamura S, Baba S, Moriya Y, Hirohashi S. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 2000; 59: 302-309
7. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage ciinical colon cancer. Gastroenterology 2002; 122: 60-71
8. Miyamoto S, Endoh Y, Hasebe T, Ishii G, Kodama K, Goya M, Ono M, Saitoh N, Chiba T, Ochiai A. Nuclear beta-catenin accumulation as a prognostic factor in Dukes' D human colorectal cancers. Oncol Rep 2004; 12: 245-251
9. Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, Linne T, Frodin JE, Boussard B, Oulid-Aissa D, Pyrhonen S. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002; 13: 1868-1873
10. Elzagheid A, Kuopio T, Ilmen M, Collan Y. Prognostication of invasive ductal breast cancer by quantification of E-cadherin immunostaining: the methodology and clinical relevance. Histopathology 2002; 41: 127-133
11. Elzagheid A, Algars A, Bendardaf R, Lamlum. H, Ristamaki R, Collan Y, Syrjanen K, Pyrhonen S. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol 2006; 12: 4304-4309
12. Lipponen P, Collan Y. Simple quantitation of immunohistochemical staining positivity in microscopy. Acta Stereol 1992; 11: 125-132
13. Bendardaf R, Elzagheid A, Lamlum, H, Ristamaki R, Collan Y, Pyrhonen S. E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer. Oncol Rep 2005; 13: 831-835
14. Mikami T. Mitomi H, Hara A, Yanagisawa N, Yoshida T, Tsuruta O, Okayasu I. Decreased expression of CD44, alpha-catenin, and deleted colon carcinoma and altered expression of beta-catenin in ulcerative colitis-associated dysplasia and carcinoma, as compared with sporadic colon neoplasms. Cancer 2000; 89: 733-740
15. Horkko TT, Klintrup K, Makinen JM, Napankangas JB, Tuominen HJ, Makela J, Karttunen TJ, Makinen MJ. Budding invasive margin and prognosis in colorectal cancer - no direct association with beta-catenia expression. Eur J Cancer 2006; 42: 964-971
16. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 2004; 10: 1401-1408
17. Roca F, Mauro LV, Morandi A, Bonadeo F, Vaccaro C, Quintana GO, Specterman S, de Kier Joffe EB, Pallotta MG, Puricelli LI, Lastiri J. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol 2006; 93: 151-160
18. Zhang B, Ougolkov A, Yamashita K, Takahashi Y, Mai M, Minamoto T. beta-Catenin and ras oncogenes detect most human colorectal cancer. Clin Cancer Res 2003; 9: 3073-3079
19. Baldus SE, Monig SP, Huxel S, Landsberg S, Ranisch FG, Engelmann K, Schneider PM, Thiele J, Holscher AH, Dienes HP. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 2004; 10: 2790-2796
20. Feng Han Q, Zhao W, Bentel J, Shearwood AM, Zeps N, Joseph D, Iacopetta B, Dharmarajan A. Expression of sFRP-4 and beta-catenin in human colorectal carcinoma. Cancer Lett 2006; 231: 129-137
21. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000; 119: 854-865
22. Loeb LA. A mutator phenotype in cancer. Cancer Res 2001; 61: 3230-3239
23. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, Rubio C, Koizumi K, Hirakawa K, Boland CR. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 2001; 61: 2676-2683
24. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, Rahkonen O, Laato M. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714-723
25. Green DW, Roh H, Pippin JA, Drebin JA. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res 2001; 101: 16-20
26. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res 2001; 7: 4013-4020
27. Mareel M, Boterberg T, Noc V, Van Hoorde L, Vermeulen S, Bruyneel E, Bracke M. E-eadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol 1997; 173: 271-274
28. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-1487
29. Bonitsis N, Batistatou A, Karantima S, Charalabopoulos K. The role of cadherin/catenin complex in malignant melanoma. Exp Oncol 2006; 28: 187-193
30. Munro SB, Blaschuk OW. A comprehensive survey of the cadherins expressed in the testes of fetal, immature, and adult mice utilizing the polymerase chain reaction. Biol Reprod 1996; 55: 822-827
31. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E-cadherin mediated adhesion system in cancer cells. Cancer 1996; 77: 1605-1613